Burger chain Five Guys flips debt with £185m refinancing
Sky News understands that Five Guys, which launched in the UK in 2013, has landed a new five-year debt deal with lenders including Britain's major high street banks.
Sources said the agreement was likely to be announced on Wednesday.
Money latest: Economists issue warning as government borrowing soars
Five Guys trades from nearly 180 sites in the UK, employing roughly 5,500 people.
It also operates under the same corporate ownership structure in France, Germany and Spain, with its European operations in total employing about 9,000 people.
ADVERTISEMENT
The European business is a 50-50 joint venture between Freston Ventures - the investment vehicle of Sir Charles Dunstone, co-founder of The Carphone Warehouse - and the Murrell family which founded Five Guys in the US.
It is now expected to seek to open a larger number of drive-thru restaurants in the UK and elsewhere in Europe.
In a statement issued to Sky News, John Eckbert, Five Guys Europe's chief executive, said: "Securing additional debt capital at a more favourable rate in today's market is a significant accomplishment.
"This £185m refinancing transaction is a testament to the strength of the Five Guys brand and our successful operational performance.
"The latest capital injection will be instrumental in accelerating our expansion strategy."
The deal comes as hospitality groups warn of an increasing challenge to survive following tax increases announced in Rachel Reeves's Budget last autumn, with chains such as Cote now exploring urgent sale processes in a bid to secure new investment.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
6 minutes ago
- Yahoo
Bel Group H1 profits decline despite higher sales
Bel Group has reported a fall in first-half earnings despite seeing its sales rise as costs ate into the French dairy group's profitability. The Boursin owner saw its share of consolidated net profit fell by 5.4% on a reported basis to €45.8m ($53m). Bel said its recurring operating income was €125m in the first half of the year, down 19.3% on the corresponding period of 2024. The company behind cheese brands The Laughing Cow and Babybel said it had seen "persistent inflation in raw materials in several markets'. Bel reported consolidated net sales of €1.86bn, marking a 3.2% organic increase, and 2% on a reported basis. The company said the growth was "driven by higher volumes and price increases". According to Bel Group CEO Cécile Béliot, the period was marked by an 'unstable geopolitical environment'. However, she added: 'Our resilient sales volumes reflect the strong value our brands deliver to consumers worldwide. 'The growth we have achieved across our geographies and categories, combined with our ongoing digital transformation, is reinforcing both our agility and operational efficiency going forward." Bel's volumes were impacted by geopolitical tensions in the Middle East and increased consumer sensitivity to price pressures, the group added. The company's 'core brands' put in a "robust performance", Bel said. Kiri saw first-half sales rise 8.2%, Mini Babybel by 6.1% and Boursin by 7.3%. In terms of geography, Bel's business in North America recorded an increase of nearly 6%. In Europe, the company maintained a positive trajectory with a 2.3% rise despite a 'slight dip' in volumes. The North Africa and Middle East region, affected by 'macroeconomic and geopolitical uncertainties', posted a 0.2% rise in sales. In June, Bel Group said it would discontinue its plant-based cheese brand Nurishh due to difficulties in making the dairy alternative profitable. As part of the move, the group announced the closure of its production site in Saint-Nazaire. "Bel Group H1 profits decline despite higher sales " was originally created and published by Just Food, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Yahoo
6 minutes ago
- Yahoo
Evercore deal accelerates talent dash as banks anticipate M&A upturn
By Charlie Conchie, Amy-Jo Crowley and David French LONDON/NEW YORK (Reuters) -Boutique deal-making adviser Evercore accelerated its campaign to become a significant force in Europe, the world's second largest pool of M&A fees, with a purchase last week that locks in talent ahead of a possible upturn in activity. Bankers forecast a return of mega-deals following a lull in corporate deal-making linked to the uncertainty surrounding U.S. tariffs. In Europe, increased defence spending has raised the prospect of deal-making in the sector and lower interest rates could also spur activity, analysts have said. Founded in 1995 by former deputy secretary of the U.S. Treasury Roger Altman, Evercore last week bought UK advisory firm Robey Warshaw for $196 million, following senior hires in France and Italy in the last two years. Although relatively small, Robey Warshaw has advised on some of the biggest deals of the last decade in Britain, including the sale of BG Group to Shell, Comcast's takeover of Sky, and Softbank's acquisition of Arm. Evercore said the deal, which is expected to close at the beginning of the fourth quarter of 2025, would increase its standing in Britain and open up opportunities across Europe, the Middle East and Africa. The acquisition means Evercore will have more than 400 bankers across nine countries in the region. "EMEA is the focal point of our global expansion strategy,' Matthew Lindsey-Clarke, co-head of Evercore's EMEA Investment Banking business, told Reuters. "This move greatly enhances our capabilities in the UK and Europe, opening up new client opportunities in a region where we have been building up a significant presence in recent years." He said it would bolster Evercore's access to British boardrooms and the ability to work for large cap companies across the EMEA region. THE WORLD'S BIGGEST SOURCE OF M&A FEES Until now, Evercore's strength has been in the world's biggest source of M&A business, the United States. Evercore ranks eighth globally for M&A financial advice with a 9.7% market share, according to LSEG data. Its highest global placing was in the years 2019 and 2023 when it took sixth place, although it has achieved a top 10 position in this table every year since 2015. In Europe, Evercore has grown its share of the market over the last decade and has ranked in the top 20 in terms of deals advisory since 2018, according to LSEG data. It climbed to a high of eighth in deals advisory ranking last year. But it faces stiff competition. Other boutique advisers, including PJT Partners and PWP, have also made individual senior hires from rivals in Europe. Banks have scooped up advisory firms. In 2023, Mizuho Financial Group bought Greenhill for $550 million and Mediobanca purchased London-based Arma Partners for an undisclosed amount. The United States' largest banks, including JP Morgan and Citi, over the last two years have hired aggressively globally. In April, JP Morgan said it had added more than 300 bankers across its global banking unit since the start of 2024. ALL ABOUT TALENT While Evercore has to be realistic about its size, it can focus on trying to get the best talent. "You're not going to compete against Goldman on the back of your balance sheet or your IPO underwriting capabilities of which you have none," Paul-Noël Guély, founder and managing partner of Arma Partners, which has around 135 staff globally, told Reuters. "You're going to be thinking I want the best bankers. And Robey Warshaw has five partners all of them extremely talented, very high-quality guys. That's exactly who Evercore want to bring on board." Founded in 2013 by veteran dealmakers Simon Robey, Simon Warshaw and Philip Apostolides, Robey Warshaw's 18 employees generated revenue of 85.8 million pounds ($113.50 million) last year, according to its latest accounts. "[Evercore] are adding the talent of Robey [Warshaw,] just in time for another surge in deals," said investor Macrae Sykes of Gabelli Funds, which has stakes in PJT and Moelis & Co. "We see pipelines are strong, and the outlook is getting better." Evercore is also doing its best to hold on to its new hires after banks have been vocal about the increased costs of retaining talent. Robey Warshaw's partners will be given incentives to stay at Evercore with payments of stock and cash over six years, according to regulatory filings. The deal has also been set up with an initial payment of Evercore stock at closing and a second payment in stock or cash at the one-year anniversary of the deal. Charles Talbot, managing director at headhunting firm Wyndham Partners, said there was an emerging trend in which deals advisory firms were seeking increased time commitments from their senior hires. "We have worked on MD hires where clients are asking for a five-year clawback on make-whole, sign-on and guarantee bonus payments," he said. ($1 = 0.7560 pounds) Sign in to access your portfolio
Yahoo
6 minutes ago
- Yahoo
BioNTech's Q2 revenues double on higher COVID vaccine sales
FRANKFURT (Reuters) -German biotech firm BioNTech on Monday said that second-quarter revenues more than doubled to 261 million euros ($302 million), driven by higher revenues from its COVID-19 vaccine collaboration with Pfizer. The company's quarterly net loss came in at 387 million euros, an improvement over a net loss of 808 million in the year-earlier period, which at the time was burdened by provisions for a settlement with the U.S. National Institutes of Health over vaccine royalty payments. Lower operating expenses also helped reduce the second-quarter loss, it added. BioNTech reiterated its guidance for 2025 revenues of 1.7 billion to 2.2 billion euros, down from 2.75 billion last year. BioNTech in June agreed to acquire domestic peer CureVac in a $1.25 billion share deal, boosting its work on new mRNA-based cancer treatments and quelling patent litigation brought by the takeover target. That was shortly after Bristol Myers Squibb agreed to pay up to $11.1 billion for rights to jointly develop BioNTech's next-generation cancer immunotherapy. ($1 = 0.8654 euros) Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
